<p>根据 Donoghue Forlines LLC 最近向证券交易委员会提交的文件，该公司在第一季度购买了辉瑞公司（NYSE:PFE - 免费报告）的新股份。该基金购买了 56,592 股生物制药公司的股票，价值约为 1,434,000 美元。</p>
<ul>
<li>医疗保健股票估值触底，3 只股票有望反弹</li>
</ul>
<p>其他机构投资者也对该公司的持仓进行了调整。Zions Bancorporation National Association UT 在第一季度新购入辉瑞的股份，价值约为 6,972,000 美元。Townsquare Capital LLC 在第一季度将其在辉瑞的持股增加了 34.3%。Townsquare Capital LLC 目前拥有辉瑞的 549,692 股股票，价值 13,929,000 美元，此前在上个季度又购买了 140,342 股。Founders Financial Alliance LLC 在第一季度将其在辉瑞的持股增加了 2.8%。Founders Financial Alliance LLC 目前拥有辉瑞的 28,180 股股票，价值 714,000 美元，此前在上个季度又购买了 763 股。Everett Harris &amp; Co. CA 在第一季度将其在辉瑞的持股增加了 5.6%。Everett Harris &amp; Co. CA 目前拥有辉瑞的 236,761 股股票，价值 6,000,000 美元，此前在上个季度又购买了 12,508 股。最后，Forsta AP Fonden 在第一季度将其在辉瑞的持股增加了 4.9%。Forsta AP Fonden 目前拥有辉瑞的 1,450,800 股股票，价值 36,763,000 美元，此前在上个季度又购买了 67,300 股。目前 68.36% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师设定新目标价</h2>
<p>多家研究分析师最近对该股票发布了报告。Wolfe Research 将辉瑞的目标价从 22.00 美元上调至 23.00 美元，并在 4 月 30 日的研究报告中给予该公司 “表现不佳” 的评级。花旗集团将辉瑞的目标价从 25.00 美元上调至 26.00 美元，并在周三的研究报告中给予该公司 “中性” 的评级。Leerink Partners 将辉瑞的目标价从 28.00 美元下调至 26.00 美元，并在 4 月 30 日的研究报告中对该股票设定了 “市场表现” 的评级。Cantor Fitzgerald 在 4 月 22 日的研究报告中开始覆盖辉瑞，给予 “中性” 评级和 24.00 美元的目标价。最后，高盛集团将辉瑞的目标价从 25.00 美元上调至 27.00 美元，并在 4 月 30 日的研究报告中给予该公司 “中性” 的评级。一位研究分析师对该股票给予了卖出评级，十一位给予持有评级，五位给予买入评级，二位给予强烈买入评级。根据 MarketBeat 的数据，辉瑞目前的平均评级为 “持有”，共识目标价为 28.12 美元。</p>
<ul>
<li>5 只被低估的高分红股票，具有强劲的派息潜力</li>
</ul>
<p><strong>阅读我们关于辉瑞的最新股票报告</strong></p>
<h2>辉瑞股票表现</h2>
<p>周五，NYSE PFE 的开盘价为 24.57 美元。该公司的 50 日简单移动平均为 24.44 美元，200 日简单移动平均为 24.50 美元。该公司的速动比率为 0.96，流动比率为 1.16，债务与股本比率为 0.65。辉瑞公司的 12 个月低点为 20.92 美元，12 个月高点为 30.43 美元。该公司的市值为 1396.9 亿美元，市盈率为 13.07，PEG 比率为 0.87，贝塔值为 0.52。</p>
<ul>
<li>辉瑞的 7.5% 股息：收入避风港还是纸牌屋？</li>
</ul>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 8 月 5 日发布了其财报。这家生物制药公司报告本季度每股收益为 0.78 美元，超出分析师共识预期的 0.58 美元，超出幅度为 0.20 美元。该公司在本季度的收入为 146.5 亿美元，而分析师预期为 134.3 亿美元。辉瑞的净利润率为 16.84%，股本回报率为 21.42%。辉瑞本季度的收入同比增长 10.3%。在去年同期，该公司每股收益为 0.60 美元。平均而言，股票分析师预测辉瑞公司今年将发布 2.95 美元的每股收益。</p>
<h2>辉瑞宣布分红</h2>
<p>该公司最近还披露了季度分红，将于 9 月 2 日（星期二）支付。7 月 25 日的股东将获得每股 0.43 美元的分红。这代表着每年 1.72 美元的分红和 7.0% 的收益率。该分红的除息日为 7 月 25 日。辉瑞目前的派息比率为 91.49%。</p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际市场发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；满足医疗需求的传染病，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>如何利用高贝塔股票最大化投资收益</li>
<li>Airbnb 超出收益预期，但增长故事正在失去高度</li>
<li>为什么这些公司被视为蓝筹股？</li>
<li>Netflix 的多头与空头：谁能赢得这次回调？</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>Viasat：为什么一大笔现金让空头们四处逃窜</li>
</ul>
<p><strong>想看看其他对冲基金持有的 PFE 吗？</strong> 访问 HoldingsChannel.com，获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。有关此故事的任何问题或评论，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>Donoghue Forlines LLC 在第一季度收购了 56,592 股辉瑞（NYSE:PFE），价值约 143 万美元。其他机构投资者也增加了对辉瑞的持股。分析师们调整了辉瑞的目标价格，普遍目标为 28.12 美元。辉瑞的股票开盘价为 24.57 美元，市值为 1396.9 亿美元。该公司报告每股收益为 0.78 美元，超出预期，并宣布季度股息为每股 0.43 美元，收益率为 7.0%</p>

<p>Donoghue Forlines LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 56,592 shares of the biopharmaceutical company's stock, valued at approximately $1,434,000.</p>
<div class="lb-trans"><p>根据 Donoghue Forlines LLC 最近向证券交易委员会提交的文件，该公司在第一季度购买了辉瑞公司（NYSE:PFE - 免费报告）的新股份。该基金购买了 56,592 股生物制药公司的股票，价值约为 1,434,000 美元。</p>
</div><ul>
<li>Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗保健股票估值触底，3 只股票有望反弹</li>
</ul>
</div><p>Other institutional investors have also made changes to their positions in the company. Zions Bancorporation National Association UT acquired a new stake in Pfizer in the 1st quarter worth approximately $6,972,000. Townsquare Capital LLC lifted its holdings in Pfizer by 34.3% in the 1st quarter. Townsquare Capital LLC now owns 549,692 shares of the biopharmaceutical company's stock worth $13,929,000 after purchasing an additional 140,342 shares during the last quarter. Founders Financial Alliance LLC lifted its holdings in Pfizer by 2.8% in the 1st quarter. Founders Financial Alliance LLC now owns 28,180 shares of the biopharmaceutical company's stock worth $714,000 after purchasing an additional 763 shares during the last quarter. Everett Harris &amp; Co. CA lifted its holdings in Pfizer by 5.6% in the 1st quarter. Everett Harris &amp; Co. CA now owns 236,761 shares of the biopharmaceutical company's stock worth $6,000,000 after purchasing an additional 12,508 shares during the last quarter. Finally, Forsta AP Fonden grew its stake in Pfizer by 4.9% in the 1st quarter. Forsta AP Fonden now owns 1,450,800 shares of the biopharmaceutical company's stock valued at $36,763,000 after buying an additional 67,300 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者也对该公司的持仓进行了调整。Zions Bancorporation National Association UT 在第一季度新购入辉瑞的股份，价值约为 6,972,000 美元。Townsquare Capital LLC 在第一季度将其在辉瑞的持股增加了 34.3%。Townsquare Capital LLC 目前拥有辉瑞的 549,692 股股票，价值 13,929,000 美元，此前在上个季度又购买了 140,342 股。Founders Financial Alliance LLC 在第一季度将其在辉瑞的持股增加了 2.8%。Founders Financial Alliance LLC 目前拥有辉瑞的 28,180 股股票，价值 714,000 美元，此前在上个季度又购买了 763 股。Everett Harris &amp; Co. CA 在第一季度将其在辉瑞的持股增加了 5.6%。Everett Harris &amp; Co. CA 目前拥有辉瑞的 236,761 股股票，价值 6,000,000 美元，此前在上个季度又购买了 12,508 股。最后，Forsta AP Fonden 在第一季度将其在辉瑞的持股增加了 4.9%。Forsta AP Fonden 目前拥有辉瑞的 1,450,800 股股票，价值 36,763,000 美元，此前在上个季度又购买了 67,300 股。目前 68.36% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research analysts recently issued reports on the stock. Wolfe Research raised their target price on shares of Pfizer from $22.00 to $23.00 and gave the company an &#34;underperform&#34; rating in a research note on Wednesday, April 30th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday. Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a &#34;market perform&#34; rating on the stock in a research note on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a &#34;neutral&#34; rating and a $24.00 price objective for the company. Finally, The Goldman Sachs Group increased their price objective on Pfizer from $25.00 to $27.00 and gave the company a &#34;neutral&#34; rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Pfizer presently has an average rating of &#34;Hold&#34; and a consensus target price of $28.12.</p>
<div class="lb-trans"><p>多家研究分析师最近对该股票发布了报告。Wolfe Research 将辉瑞的目标价从 22.00 美元上调至 23.00 美元，并在 4 月 30 日的研究报告中给予该公司 “表现不佳” 的评级。花旗集团将辉瑞的目标价从 25.00 美元上调至 26.00 美元，并在周三的研究报告中给予该公司 “中性” 的评级。Leerink Partners 将辉瑞的目标价从 28.00 美元下调至 26.00 美元，并在 4 月 30 日的研究报告中对该股票设定了 “市场表现” 的评级。Cantor Fitzgerald 在 4 月 22 日的研究报告中开始覆盖辉瑞，给予 “中性” 评级和 24.00 美元的目标价。最后，高盛集团将辉瑞的目标价从 25.00 美元上调至 27.00 美元，并在 4 月 30 日的研究报告中给予该公司 “中性” 的评级。一位研究分析师对该股票给予了卖出评级，十一位给予持有评级，五位给予买入评级，二位给予强烈买入评级。根据 MarketBeat 的数据，辉瑞目前的平均评级为 “持有”，共识目标价为 28.12 美元。</p>
</div><ul>
<li>Top 5 Undervalued Dividend Stocks With Strong Payout Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只被低估的高分红股票，具有强劲的派息潜力</li>
</ul>
</div><p><strong>Read Our Latest Stock Report on Pfizer</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于辉瑞的最新股票报告</strong></p>
</div><h2>Pfizer Stock Performance</h2>
<div class="lb-trans"><h2>辉瑞股票表现</h2>
</div><p>NYSE PFE opened at $24.57 on Friday. The company has a 50-day simple moving average of $24.44 and a two-hundred day simple moving average of $24.50. The company has a quick ratio of 0.96, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The firm has a market cap of $139.69 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 0.87 and a beta of 0.52.</p>
<div class="lb-trans"><p>周五，NYSE PFE 的开盘价为 24.57 美元。该公司的 50 日简单移动平均为 24.44 美元，200 日简单移动平均为 24.50 美元。该公司的速动比率为 0.96，流动比率为 1.16，债务与股本比率为 0.65。辉瑞公司的 12 个月低点为 20.92 美元，12 个月高点为 30.43 美元。该公司的市值为 1396.9 亿美元，市盈率为 13.07，PEG 比率为 0.87，贝塔值为 0.52。</p>
</div><ul>
<li>Pfizer's 7.5% Dividend: Income Haven or House of Cards?</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞的 7.5% 股息：收入避风港还是纸牌屋？</li>
</ul>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.60 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 8 月 5 日发布了其财报。这家生物制药公司报告本季度每股收益为 0.78 美元，超出分析师共识预期的 0.58 美元，超出幅度为 0.20 美元。该公司在本季度的收入为 146.5 亿美元，而分析师预期为 134.3 亿美元。辉瑞的净利润率为 16.84%，股本回报率为 21.42%。辉瑞本季度的收入同比增长 10.3%。在去年同期，该公司每股收益为 0.60 美元。平均而言，股票分析师预测辉瑞公司今年将发布 2.95 美元的每股收益。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>辉瑞宣布分红</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is presently 91.49%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，将于 9 月 2 日（星期二）支付。7 月 25 日的股东将获得每股 0.43 美元的分红。这代表着每年 1.72 美元的分红和 7.0% 的收益率。该分红的除息日为 7 月 25 日。辉瑞目前的派息比率为 91.49%。</p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际市场发现、开发、制造、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；满足医疗需求的传染病，品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及潜在的未来 mRNA 和抗病毒产品，品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Viasat: Why a Wall of Cash Has Shorts Running for Cover</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>如何利用高贝塔股票最大化投资收益</li>
<li>Airbnb 超出收益预期，但增长故事正在失去高度</li>
<li>为什么这些公司被视为蓝筹股？</li>
<li>Netflix 的多头与空头：谁能赢得这次回调？</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>Viasat：为什么一大笔现金让空头们四处逃窜</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 PFE 吗？</strong> 访问 HoldingsChannel.com，获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。有关此故事的任何问题或评论，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Donoghue Forlines LLC Buys Shares of 56,592 Pfizer Inc. (NYSE:PFE)

- Donoghue Forlines LLC 在第一季度购买了 Pfizer 的 56,592 股股票，价值约 143.4 万美元。  
- 其他机构投资者也增加了在 Pfizer 的持股，Zions Bancorporation 购买了约 697.2 万美元的股份。  
- Pfizer 最近公布的季度收益为每股 0.78 美元，超出分析师预期。  

Donoghue Forlines LLC 购入了 56,592 股辉瑞公司（NYSE 代码：PFE）的股票